patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_119817 | REC_0012701 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.4 | 73 | female | 1 | 47 | 7.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:36:00.082851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329984 | REC_0012702 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 2.9 | 71 | female | 2 | 17 | 5.7 | 7 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:36:00.083346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150248 | REC_0012703 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.6 | 79 | female | 1 | 70 | 6.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 23 | true | MSS | 2026-03-15T05:36:00.083707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618496 | REC_0012704 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 17.3 | 76 | female | 2 | 17 | 5.9 | 8 | sotorasib 960 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:00.084063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554801 | REC_0012705 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 8.4 | 65 | male | 1 | 11 | 5.7 | 0 | osimertinib 80 mg daily | 22.4 | true | MSS | 2026-03-15T05:36:00.084517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939847 | REC_0012706 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.8 | 68 | male | 1 | 11 | 5.4 | 5 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:00.084896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466229 | REC_0012707 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.3 | 85 | female | 1 | 21 | 7.4 | 2 | alectinib 600 mg BID | 16.5 | true | MSS | 2026-03-15T05:36:00.085278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385117 | REC_0012708 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.5 | 65 | male | 1 | 20 | 6.5 | 4 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:00.085655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565599 | REC_0012709 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 14.7 | 64 | male | 1 | 17 | 4.2 | 4 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.086036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580966 | REC_0012710 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.1 | 72 | female | 2 | 19 | 5.2 | 4 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:00.086432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335028 | REC_0012711 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.1 | 69 | female | 0 | 6 | 8.2 | 2 | alectinib 600 mg BID | 6.7 | true | MSI-H | 2026-03-15T05:36:00.086819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116766 | REC_0012712 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 22 | 5.4 | 64 | male | 1 | 26 | 6 | 0 | pembrolizumab 200 mg q3w | 41.1 | false | MSS | 2026-03-15T05:36:00.087199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983063 | REC_0012713 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 16.2 | 51 | male | 0 | 7 | 5.4 | 0 | sotorasib 960 mg daily | 30.3 | false | MSS | 2026-03-15T05:36:00.087591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613486 | REC_0012714 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 15 | 12.4 | 57 | female | 0 | 0 | 5.4 | 3 | pembrolizumab 200 mg q3w | 16.4 | false | MSS | 2026-03-15T05:36:00.087941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748387 | REC_0012715 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.3 | 54 | male | 0 | 22 | 3 | 9 | sotorasib 960 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:36:00.088603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397029 | REC_0012716 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.6 | 55 | female | 1 | 18 | 6.4 | 1 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:00.089001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335804 | REC_0012717 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.3 | 75 | female | 1 | 22 | 7 | 6 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:36:00.089344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488475 | REC_0012718 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.5 | 65 | female | 1 | 16 | 5.6 | 2 | alectinib 600 mg BID | 8.4 | true | MSS | 2026-03-15T05:36:00.089664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557045 | REC_0012719 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 5.6 | 69 | female | 1 | 19 | 6 | 7 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:00.089963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488597 | REC_0012720 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.7 | 62 | female | 0 | 93 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.2 | true | MSS | 2026-03-15T05:36:00.090269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304664 | REC_0012721 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.5 | 78 | female | 2 | 13 | 6.5 | 5 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:36:00.090584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825536 | REC_0012722 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 13.5 | 74 | male | 2 | 11 | 5.7 | 1 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:00.090883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508847 | REC_0012723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.7 | 66 | female | 1 | 13 | 4.2 | 7 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:36:00.091182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366810 | REC_0012724 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.1 | 62 | female | 1 | 20 | 5.4 | 8 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:36:00.091465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358819 | REC_0012725 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.2 | 69 | male | 0 | 9 | 5.8 | 5 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:00.091733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592212 | REC_0012726 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.3 | 61 | male | 1 | 18 | 5.3 | 5 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:36:00.091995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753667 | REC_0012727 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.5 | 61 | male | 0 | 11 | 6.2 | 1 | alectinib 600 mg BID | 15.1 | true | MSS | 2026-03-15T05:36:00.092393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866561 | REC_0012728 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 18 | 64 | female | 0 | 14 | 7.4 | 1 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:00.092806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440489 | REC_0012729 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19.2 | 63 | female | 1 | 15 | 4.3 | 5 | sotorasib 960 mg daily | 6.6 | true | MSS | 2026-03-15T05:36:00.093109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936330 | REC_0012730 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.6 | 64 | male | 0 | 69 | 5.3 | 6 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:00.093379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797114 | REC_0012731 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 8.7 | 84 | female | 2 | 15 | 5 | 3 | sotorasib 960 mg daily | 16.6 | false | MSS | 2026-03-15T05:36:00.093640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385131 | REC_0012732 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 12.7 | 72 | female | 1 | 15 | 5.2 | 5 | pembrolizumab 200 mg q3w | 8.8 | true | MSI-H | 2026-03-15T05:36:00.093912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775623 | REC_0012733 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 8 | 63 | female | 1 | 14 | 6.6 | 1 | pembrolizumab 200 mg q3w | 16.9 | true | MSS | 2026-03-15T05:36:00.094189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651465 | REC_0012734 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.2 | 62 | female | 1 | 17 | 5.1 | 7 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:36:00.094460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885004 | REC_0012735 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 30 | 13.2 | 68 | female | 0 | 17 | 6.1 | 0 | osimertinib 80 mg daily | 43 | false | MSS | 2026-03-15T05:36:00.094748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144902 | REC_0012736 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 11 | 62 | female | 0 | 5 | 5.7 | 2 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:36:00.095057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281999 | REC_0012737 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 3.5 | 69 | female | 1 | 15 | 4 | 7 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:36:00.095373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534344 | REC_0012738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.4 | 66 | female | 0 | 12 | 5.7 | 5 | entrectinib 600 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:36:00.095689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152384 | REC_0012739 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.9 | 75 | male | 2 | 11 | 7.2 | 5 | sotorasib 960 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:00.095985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445885 | REC_0012740 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 13 | 7.3 | 59 | male | 1 | 81 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:36:00.096365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316869 | REC_0012741 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.6 | 73 | female | 2 | 53 | 4.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:36:00.096901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109482 | REC_0012742 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 17.8 | 54 | male | 0 | 8 | 6.1 | 1 | alectinib 600 mg BID | 17.7 | true | MSI-H | 2026-03-15T05:36:00.097273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502776 | REC_0012743 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 7.4 | 82 | female | 1 | 10 | 4.7 | 6 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.097569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443153 | REC_0012744 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 18.5 | 66 | female | 1 | 20 | 6 | 0 | osimertinib 80 mg daily | 35.5 | false | MSS | 2026-03-15T05:36:00.097894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575370 | REC_0012745 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 18 | 3.8 | 63 | female | 1 | 34 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 46.4 | true | MSS | 2026-03-15T05:36:00.098228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930024 | REC_0012746 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 9.9 | 61 | female | 0 | 15 | 5.3 | 2 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:36:00.098598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168743 | REC_0012747 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.1 | 72 | female | 1 | 14 | 6.7 | 2 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:36:00.098978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662323 | REC_0012748 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.6 | 56 | female | 1 | 74 | 3.1 | 5 | pembrolizumab 200 mg q3w | 7.7 | true | MSS | 2026-03-15T05:36:00.099354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230720 | REC_0012749 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.9 | 71 | female | 1 | 12 | 4.6 | 3 | osimertinib 80 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:36:00.099694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804966 | REC_0012750 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 17 | 11 | 69 | female | 0 | 10 | 5.5 | 0 | alectinib 600 mg BID | 26.4 | false | MSI-H | 2026-03-15T05:36:00.099996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338050 | REC_0012751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 16.9 | 74 | male | 1 | 17 | 4.9 | 1 | alectinib 600 mg BID | 22.8 | false | MSS | 2026-03-15T05:36:00.101609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857932 | REC_0012752 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.3 | 56 | female | 0 | 21 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:36:00.102008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906894 | REC_0012753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.4 | 81 | female | 3 | 22 | 5.9 | 4 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.102343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943113 | REC_0012754 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8.8 | 58 | male | 0 | 12 | 4.1 | 1 | osimertinib 80 mg daily | 17 | false | MSS | 2026-03-15T05:36:00.102826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397366 | REC_0012755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.6 | 55 | male | 1 | 70 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:36:00.103181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586418 | REC_0012756 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 8.5 | 62 | male | 0 | 15 | 4.7 | 2 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:36:00.103524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220485 | REC_0012757 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 10.9 | 81 | female | 2 | 30 | 5.2 | 0 | osimertinib 80 mg daily | 19.1 | true | MSS | 2026-03-15T05:36:00.103848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636462 | REC_0012758 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 11.4 | 70 | female | 1 | 14 | 2.7 | 0 | alectinib 600 mg BID | 37.5 | true | MSS | 2026-03-15T05:36:00.104251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323368 | REC_0012759 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 7.2 | 55 | male | 0 | 56 | 5 | 0 | carboplatin + paclitaxel + pembrolizumab | 32.8 | true | MSS | 2026-03-15T05:36:00.104610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811582 | REC_0012760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.8 | 67 | female | 0 | 23 | 6.6 | 5 | osimertinib 80 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:36:00.104925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614072 | REC_0012761 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 9.2 | 72 | female | 1 | 10 | 7 | 2 | sotorasib 960 mg daily | 18.7 | false | MSS | 2026-03-15T05:36:00.105242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744216 | REC_0012762 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.3 | 59 | female | 0 | 16 | 5.3 | 5 | pembrolizumab 200 mg q3w | 5.1 | true | MSS | 2026-03-15T05:36:00.105546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149489 | REC_0012763 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 39 | 11.8 | 68 | female | 1 | 13 | 5.8 | 1 | entrectinib 600 mg daily | 22.2 | false | MSS | 2026-03-15T05:36:00.105855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850835 | REC_0012764 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 16.7 | 70 | male | 1 | 21 | 4 | 1 | alectinib 600 mg BID | 21.5 | true | MSS | 2026-03-15T05:36:00.106159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245496 | REC_0012765 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.1 | 61 | female | 0 | 18 | 6.8 | 5 | osimertinib 80 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:00.106454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143287 | REC_0012766 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 10.9 | 83 | female | 2 | 14 | 8.1 | 2 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:36:00.106745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867281 | REC_0012767 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.2 | 72 | female | 2 | 23 | 4.8 | 7 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:36:00.107197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947604 | REC_0012768 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 18.6 | 52 | female | 0 | 9 | 7.5 | 2 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:00.107526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643063 | REC_0012769 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.7 | 58 | male | 0 | 18 | 6.2 | 3 | entrectinib 600 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:36:00.107812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958670 | REC_0012770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10 | 77 | female | 2 | 8 | 7.9 | 4 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:36:00.108557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244727 | REC_0012771 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14.2 | 57 | male | 0 | 14 | 5.8 | 9 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:00.109022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383327 | REC_0012772 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.8 | 53 | male | 0 | 19 | 5.5 | 7 | alectinib 600 mg BID | 10.9 | true | MSI-H | 2026-03-15T05:36:00.109361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835108 | REC_0012773 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.7 | 72 | female | 2 | 50 | 3.9 | 3 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:00.109671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589054 | REC_0012774 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.9 | 72 | female | 2 | 12 | 5.8 | 1 | alectinib 600 mg BID | 16.3 | true | MSI-H | 2026-03-15T05:36:00.109973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152375 | REC_0012775 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 14.9 | 69 | female | 1 | 9 | 6.2 | 2 | sotorasib 960 mg daily | 30.1 | true | MSS | 2026-03-15T05:36:00.110264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598579 | REC_0012776 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 4 | 83 | female | 2 | 4 | 4.6 | 5 | sotorasib 960 mg daily | 6.2 | false | MSS | 2026-03-15T05:36:00.110560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842410 | REC_0012777 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.6 | 62 | male | 1 | 9 | 4.6 | 2 | osimertinib 80 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:36:00.111021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468243 | REC_0012778 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 7.1 | 67 | female | 0 | 35 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 20 | true | MSS | 2026-03-15T05:36:00.111378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130072 | REC_0012779 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 29 | 9.8 | 64 | male | 0 | 13 | 5.3 | 0 | pembrolizumab 200 mg q3w | 27 | true | MSS | 2026-03-15T05:36:00.111692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627096 | REC_0012780 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 9 | 69 | female | 0 | 18 | 4.6 | 2 | osimertinib 80 mg daily | 18.7 | true | MSS | 2026-03-15T05:36:00.112230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434267 | REC_0012781 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 17 | 75 | female | 2 | 13 | 6.3 | 2 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:36:00.112592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483911 | REC_0012782 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.8 | 76 | female | 2 | 8 | 5.2 | 6 | alectinib 600 mg BID | 12.2 | false | MSI-H | 2026-03-15T05:36:00.112911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861479 | REC_0012783 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.9 | 76 | male | 2 | 8 | 7.9 | 2 | osimertinib 80 mg daily | 17 | false | MSI-H | 2026-03-15T05:36:00.113231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887774 | REC_0012784 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.4 | 63 | female | 0 | 21 | 4.6 | 6 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.113546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314442 | REC_0012785 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 13.3 | 65 | male | 1 | 12 | 4.5 | 1 | pembrolizumab 200 mg q3w | 19.5 | false | MSI-H | 2026-03-15T05:36:00.113852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214450 | REC_0012786 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.7 | 54 | male | 0 | 14 | 3.8 | 5 | alectinib 600 mg BID | 9.3 | true | MSS | 2026-03-15T05:36:00.114142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254097 | REC_0012787 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 11.2 | 63 | female | 0 | 8 | 6 | 6 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.114436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498635 | REC_0012788 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 3.1 | 72 | female | 2 | 15 | 5.2 | 5 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:00.114727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308253 | REC_0012789 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.3 | 88 | male | 1 | 34 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:00.115036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192944 | REC_0012790 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 13 | 48 | female | 0 | 12 | 6.6 | 0 | sotorasib 960 mg daily | 41.5 | true | MSI-H | 2026-03-15T05:36:00.115371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134451 | REC_0012791 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 8.6 | 76 | female | 2 | 13 | 7.7 | 1 | entrectinib 600 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:00.115679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182191 | REC_0012792 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 8.2 | 77 | female | 2 | 11 | 3.1 | 5 | entrectinib 600 mg daily | 20 | false | MSS | 2026-03-15T05:36:00.115994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472652 | REC_0012793 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.5 | 66 | male | 0 | 7 | 6 | 6 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:36:00.116659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734230 | REC_0012794 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.4 | 57 | female | 0 | 13 | 6.8 | 5 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:00.117013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230718 | REC_0012795 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.1 | 52 | male | 0 | 11 | 5.8 | 2 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:36:00.117314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398368 | REC_0012796 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.9 | 79 | male | 2 | 16 | 5 | 1 | pembrolizumab 200 mg q3w | 22.9 | false | MSS | 2026-03-15T05:36:00.117620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461844 | REC_0012797 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12.6 | 56 | male | 1 | 20 | 7 | 0 | sotorasib 960 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:36:00.117923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336304 | REC_0012798 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.5 | 73 | female | 0 | 57 | 5 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:36:00.118199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735075 | REC_0012799 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.9 | 73 | female | 1 | 16 | 7.3 | 5 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:36:00.118487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104861 | REC_0012800 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.8 | 74 | female | 2 | 22 | 5.6 | 1 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:36:00.118810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.